Approval · Notice of Compliance 29131 · 2022
EXELON PATCH 10: Notice of Compliance 29131
Issued October 3, 2022
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 29131
- Date
- October 3, 2022
- Company
- Knight Therapeutics Inc.Montreal, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- Admin
- Reason
- Administrative: Change in Product Ownership
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| EXELON PATCH 10 | 02302853 | Marketed |
| EXELON PATCH 15 | 02432803 | Marketed |
| EXELON PATCH 5 | 02302845 | Marketed |
Medicinal ingredients
- RIVASTIGMINE 9.5 MG per DAY
- RIVASTIGMINE 13.3 MG per DAY
- RIVASTIGMINE 4.6 MG per DAY